Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза II Россия

GSK256066; Placebo

A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety and Tolerability of Inhaled GSK256066 in Mild to Moderate COPD Patients

Номер протоколаIPC101939
ФазаФаза II
Участников по плану — во всех странах исследования104
Сроки04.10.2007 — 15.12.2008
Начало: 4 октября 2007Окончание: 15 декабря 2008
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00549679/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: 40–75 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 104 чел. во всех странах исследования.
  • Плановая дата окончания (12.2008) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возраст40–75 лет
ПолЛюбой
Здоровые добровольцынет

Главное из критериев

  • ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения

Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.

Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 32

Критерии включения

  • Male adults or female adults of non-childbearing potential who are between 40 and 75 years of age (inclusive).
  • Subjects with a clinical diagnosis of COPD in accordance with the European Respiratory Society Consensus Statement and subjects categorised with moderate COPD as defined by the GOLD guidelines of 2006 \[GOLD, 2006\]
  • Subjects with a cigarette smoking history of ≥ 10 pack years (1 pack year = 20 cigarettes smoked per day for 1 year or the equivalent). Both current and former smokers are eligible to be enrolled. A former smoker is defined as a subject who has not smoked for ≥6 months at Visit 1.
  • Subjects with a post-bronchodilator FEV1 to FVC ratio (FEV1/FVC) < 0.7 at Visit 1. Subjects will be assessed 30 (± 5) minutes after receiving salbutamol 400 μg.
  • Subjects with a post-bronchodilator FEV1 ≥ 50% and < 80% of predicted normal for height, age and sex at Visit 1. Subjects will be assessed 30 (± 5) minutes after receiving salbutamol 400 μg.
  • Subjects with a normal echocardiogram at screening, as defined by the absence of clinically significant wall motion, chamber size or valvular abnormalities
  • The subject must be capable of giving informed consent and can comply with the study requirements and timetable.

Критерии невключения

  • Women who are pre-menopausal and of child-bearing potential.
  • Subjects weighing less than 50 kilograms (kg).
  • Subjects who are obese defined as having a body mass index (BMI) > 30.
  • Subjects with a current diagnosis of asthma.
  • Subjects who have required hospitalisation or treatment with oral corticosteroids and/or antibiotic therapy for acute worsening of COPD or lower respiratory tract infection in the 6 weeks prior to Screening.
  • Subjects who have received treatment with oral, intravenous, topical or intra-articular corticosteroids within 6 weeks of Screening or thereafter
  • Subjects with active tuberculosis, sarcoidosis or clinically overt bronchiectasis.
  • Subjects with a history of any type of malignancy with the exception of successfully treated squamous cell cancer of the skin.
  • Subjects with rheumatoid arthritis, connective tissue disorders and other conditions known to be associated with chronic inflammation (e.g. Inflammatory Bowel Disease).
  • Subjects with chronic infections (lasting longer than 6 months) such as gingivitis, periodontitis, prostatitis, gastritis, and urinary tract infections.
  • Subjects with any acute infection, sinus symptoms, or significant trauma (burns, fractures).
  • Subjects with clinically significant renal disease, diabetes mellitus/metabolic syndrome, hypertension or any other clinically significant cardiovascular, neurological, endocrine, or haematological abnormalities that are uncontrolled on permitted therapy.
  • Subjects who have participated in any GSK study/studies involving administration of COA.
  • The subject has a screening ECG parameters outside of ranges specified in protocol.
  • Subjects with hypoxaemia
  • Risk factors for human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C infection at Screening (Visit 1).
  • Subjects who have undergone surgery including lung volume reduction surgery in the last six months or have conditions that prevent them from performing spirometry.
  • Subjects with a history (or suspected history) of alcohol misuse or any other recreational substance abuse.
  • Subjects who require treatment with any of the following from the start of the run-in period (Day -14) until the end of the treatment phase:
  • Inhaled corticosteroids
  • Inhaled cromolyn sodium or nedocromil
  • Xanthines (theophylline preparations).
  • Leukotriene modifiers
  • Tiotropium
  • Long-acting inhaled beta2-agonists (salmeterol, formoterol)
  • Oral beta2-agonists
  • Subjects who are unable to abstain from other courses of medication during the run in phase including non-steroidal anti-inflammatory drugs (NSAIDs), anti-depressant drugs, anti-histamines, anti-rhinitis or hay fever medication, other than short acting inhaled beta-agonists, ipratropium bromide and paracetamol (up to 4 g per day) for the treatment of minor ailments (eg headache) from 48h before the first dose until the follow-up visit. Subjects requiring medication between dosing and follow up may be excluded at the principal investigators discretion.
  • Subjects with any known hypersensitivity to salbutamol or ipratropium bromide.
  • Subjects who are participating or plan to participate in the active phase of a pulmonary rehabilitation programme during the study.
  • Subjects who have received an investigational drug within 30 days or within five drug half-lives of the investigational drug (whichever is longer).
  • Subjects with any clinically relevant abnormality detected by the assessments at Screening.
  • Subjects who have experienced an exacerbation during the run-in period requiring treatment with oral corticosteroids and/or macrolide antibiotics and/or hospitalisation.

Источник: ClinicalTrials.gov, NCT00549679 · запись обновлена в реестре 28 июля 2017.

Дизайн и результаты

ДизайнРандомизированное, двойное слепое, параллельные группы; цель — лечение
Включено участников (факт, все страны)104
Результатыв реестре не опубликованы
Что измеряют — первичные конечные точки (10), вторичных — 23
  • Number of participants with adverse events (AEs) and serious adverse events (SAEs) — Up to follow up (approximately 56 days)
  • Change from Baseline (Day 0 [pre-bronchodilator]) in 12-lead electrocardiogram (ECG) findings — Baseline (Day 0 [pre-bronchodilator]) and up to Day 28 (Visit 6b)
  • Change from Baseline (Day 0 [pre-bronchodilator]) in 12-lead electrocardiogram (ECG) findings-ventricular rate — Baseline (Day 0 [pre-bronchodilator]) and up to Day 28 (Visit 6b)
  • Number of participants with abnormal (potential clinical importance [PCI]) systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) — Up to Day 27 (Visit 6a)
  • Number of participants with abnormal (PCI) clinical chemistry — Up to Day 42 (follow up visit)
  • Number of participants with abnormal (PCI) hematology — Up to Day 42 (follow up visit)
  • Number of participants with abnormal urinalysis — Up to Day 56 (Visit follow up)
  • Change from Baseline (Day 0) in lung function parameters: forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) — Baseline (Day 0) and up to Day 27 (Visit 6a)
  • Number of participants with abnormal Holter interpretations — Up to Day 27 (Visit 6a)
  • Number of participants who withdrawn for exacerbations of chronic obstructive pulmonary disease (COPD) — Up to Day 27 (Visit 6a)

Цель исследования

This study will evaluate the safety and tolerability of the cfor the first time in mild to moderate COPD patients.

Где проходит

0 центров

Центры в реестре не указаны.

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00549679 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.